Company Overview of Alder Biopharmaceuticals, Inc.
Alder Biopharmaceuticals, Inc. identifies, develops, and manufactures antibody therapeutics to alleviate human suffering in cancer, pain, cardiovascular, and autoimmune and inflammatory disease areas. Its development portfolio includes ALD518, a humanized monoclonal antibody designed to block a cytokine called interleukin-6 that plays a key role in the inflammatory cascade leading to the inflammation, swelling, pain, and joint destruction associated with rheumatoid arthritis; ALD403, a humanized monoclonal antibody that inhibits calcitonin gene-related peptide that triggers migraine attacks; and ALD306, a humanized monoclonal antibody targeting proprotein convertase subtilisin kexin 9 for ca...
11804 North Creek Parkway South
Bothell, WA 98011
Founded in 2002
Key Executives for Alder Biopharmaceuticals, Inc.
Co-Founder and Chief Scientific Officer
Vice President of Finance
Senior Vice President of Translational Medicine
Compensation as of Fiscal Year 2012.
Alder Biopharmaceuticals, Inc. Key Developments
Alder Biopharmaceuticals, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 10:40 AM
Apr 3 13
Alder Biopharmaceuticals, Inc. Presents at 12th Annual Needham Healthcare Conference, Apr-30-2013 10:40 AM. Venue: The Westin Grand Central Hotel, 212 East 42nd Street, New York, New York, United States.
Alder Biopharmaceuticals Inc. Announces the Dosing of the First Patients in Proof-Of-Concept Phase 2 Clinical Study of its Antibody Therapeutic Candidate, ALD403, Targeting calcitonin gene-related peptide (CGRP) for Treatment of Migraine
Mar 20 13
Alder Biopharmaceuticals Inc. announced the dosing of the first patients in a proof-of-concept Phase 2 clinical study of its antibody therapeutic candidate, ALD403, targeting calcitonin gene-related peptide (CGRP) for treatment of migraine. The double-blind, placebo-controlled, randomized study will evaluate the safety and efficacy of ALD403 administered monthly. One hundred and sixty patients with frequent, episodic migraines will be enrolled in the study across six sites for six months. Patients in the study will have experienced between four and 14 migraines per month in at least three months prior to enrollment and take acute migraine medication. Research has shown that CGRP has a role as a trigger for migraine attacks, and inhibiting the peptide has demonstrated promise in preventing the onset of migraines. ALD403 is expected to be developed for patients experiencing multiple migraines per month with self-administered infrequent dosing. Company's core technology enables the production of antibodies in very high quantities via its Mab Xpress technology, allowing this class of therapeutics to enter disease areas that have previously been inaccessible for antibodies, such as migraine and cardiovascular disease. Proof of concept for this technology was achieved with clazakizumab, previously known as ALD518, a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is currently under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases (BMS-945429), while Alder is developing the antibody for cancer-related conditions.
Alder Biopharmaceuticals, Inc. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Alder Biopharmaceuticals, Inc. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|